Dr. Isikwei is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
90130 Old Hwy
Tavernier, FL 33070Phone+1 305-852-9300- Is this information wrong?
Education & Training
- Windsor University School of MedicineClass of 2010
Certifications & Licensure
- FL State Medical License 2023 - 2025
Publications & Presentations
PubMed
- A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors,...Kristy L Pilbeam, Kamnesh Pradhan, James Croop, Charles G Minard, Xiaowei Liu, Stephan D Voss, Emasenyie Isikwei, Stacey L Berg, Joel M Reid, Elizabeth Fox, Brenda J W...> ;Pediatric Blood & Cancer. 2024 Mar 1
- 1 citationsFeasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.Katherine Tarlock, Xiaowei Liu, Emasenyie A Isikwei, Joel M Reid, Terzah M Horton, Elizabeth Fox, Brenda J Weigel, Todd Cooper, Minard, C.> ;Pediatric Blood & Cancer. 2023 Dec 1
- 12 citationsA Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.Kara L Davis, Elizabeth Fox, Emasenyie Isikwei, Joel M Reid, Xiaowei Liu, Charles G Minard, Stephan Voss, Stacey L Berg, Brenda J Weigel, Crystal L Mackall> ;Clinical Cancer Research. 2022 Dec 1
- Join now to see all
Journal Articles
- Risk Factors for Hypogammaglobulinemia in Chronic Lymphocytic Leukemia Patients Treated with Anti-Cd20 Monoclonal Antibody-Based TherapiesMcNulty, Caitlin M., Emasenyie A. Isikwei, Pragya Shrestha, Melissa R. Snyder, Brian F. Kabat, Kari G. Rabe, Susan L. Slager, Sameer A. Parikh, and Avni Y. Joshi, Journal of Hematopathology, 10/1/2020
Abstracts/Posters
- Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with rec...Jennifer Foster, Joel M. Reid, Charles G. Minard, Emasenyie Isikwei, Xiaowei Liu, Stacey L. Berg, Sarah Garrett Injac, Elizabeth Fox, Brenda Weigel, 2021 ASCO Annual Meeting, Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 10019-10019
- Feasibility of Pevonedistat Combined with Azacitidine, Fludarabine, Cytarabine in Pediatric Relapsed/Refractory AML: Results from COG ADVL1712Katherine Tarlock, Xiaowei Liu, Charles G. Minard, Sarah Menig, Joel M. Reid, Emasenyie Isikwei, Sharon Bergeron, Terzah M Horton, Elizabeth Fox, Brenda Weigel, Todd M..., 2021 ASCO Annual Meeting, Journal of Clinical Oncology, 5/28/2021
- Prediction of drug disposition using physiologically based pharmacokinetic (PBPK) modeling approach: Venlafaxine Extended Release formulationEmasenyie Isikwei, M.D., Julie Cunningham, Pharm.D., R.Ph, Carrie Krieger, Pharm.D., R.Ph, Joel Reid, Ph.D, ASCPT 2020, American Society for Clinical Pharmacology and Therapeutics, 9/2020
- Join now to see all
Grant Support
- NIH T32 Training GrantNIH2018–2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: